Acumen Pharmaceuticals Presents First Comprehensive Clinical and Biomarker Data for Sabirnetug (ACU193) at American Academy of Neurology 2024 Annual Meeting
16 avr. 2024 08h00 HE
|
Acumen Pharmaceuticals, Inc.
Presentation and poster include deeper data insights on sabirnetug safety profile, target engagement and fluid biomarker changesPresentation to be featured during AAN Emerging Science SessionCompany...
Acumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer’s Disease
04 avr. 2024 08h00 HE
|
Acumen Pharmaceuticals, Inc.
Lonza to manufacture Acumen’s monoclonal antibody, sabirnetug (ACU193), for clinical development and commercialization, if approvedSabirnetug is the first monoclonal antibody candidate to enter the...
Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2023 and Business Highlights
26 mars 2024 07h00 HE
|
Acumen Pharmaceuticals, Inc.
Initiation of a Phase 2 study, ALTITUDE-AD, to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease expected in the first half of 2024 Initiation of a Phase 1 study to...
Acumen Pharmaceuticals to Present Deeper Insights, Including Fluid Biomarker Data for Sabirnetug (ACU193), During Emerging Science Session at the American Academy of Neurology Annual Meeting
21 mars 2024 08h00 HE
|
Acumen Pharmaceuticals, Inc.
- Company on track to initiate Phase 2 trial evaluating sabirnetug in first half of 2024 CHARLOTTESVILLE, Va., March 21, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a...
Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2023 Financial Results on March 26, 2024
19 mars 2024 16h00 HE
|
Acumen Pharmaceuticals, Inc.
CHARLOTTESVILLE, Va., March 19, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel...
Acumen Pharmaceuticals to Participate in the Stifel 2024 CNS Days
12 mars 2024 16h00 HE
|
Acumen Pharmaceuticals, Inc.
CHARLOTTESVILLE, Va., March 12, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic...
Acumen Pharmaceuticals Presents Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer’s at the AD/PD™ 2024 Annual Meeting
08 mars 2024 08h50 HE
|
Acumen Pharmaceuticals, Inc.
- Cerebrospinal fluid (CSF) biomarker results are highly supportive of sabirnetug’s downstream pharmacological effects in the brain in early AD - Poster presentation showcases method used to develop...
Acumen Pharmaceuticals to Present Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer’s at the AD/PD™ 2024 Annual Meeting
21 févr. 2024 08h00 HE
|
Acumen Pharmaceuticals, Inc.
- Oral presentation to explore drug effect of sabirnetug (ACU193) on key cerebrospinal fluid biomarkers in early AD - Poster presentation to showcase method used to develop a first-of-its-kind...
Acumen Pharmaceuticals Appoints Dr. James Doherty as President and Chief Development Officer
01 févr. 2024 07h00 HE
|
Acumen Pharmaceuticals, Inc.
CHARLOTTESVILLE, Va., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic...
Acumen Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
04 janv. 2024 16h15 HE
|
Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals to present at the JPMorgan Healthcare Conference.